Antidepressants reduce neuroinflammatory responses and astroglial alpha-synuclein accumulation in a transgenic mouse model of multiple system atrophy

GLIA

Volumn 62, Issue 2, 2014, Pages 317-337

  Valera, Elvira ^a   Ubhi, Kiren ^a   Mante, Michael ^a   Rockenstein, Edward ^a   Masliah, Eliezer ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anti inflammation; Astroglia; Chemokine; Cytokine; Neurodegenerative disease

Indexed keywords

ALPHA SYNUCLEIN; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CXCL11 CHEMOKINE; FLUOXETINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 16; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 23; INTERLEUKIN 27; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 2; OLANZAPINE; RANTES; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTROCYTE; ASTROCYTOSIS; BASAL GANGLION; COMPARATIVE STUDY; CONTROLLED STUDY; CORPUS CALLOSUM; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FRONTAL CORTEX; HIPPOCAMPUS; IMMUNOREACTIVITY; IN VITRO STUDY; INTERNALIZATION; MACROGLIA; MOUSE; NERVOUS SYSTEM DEVELOPMENT; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHY DRAGER SYNDROME; WESTERN BLOTTING;

ANTI-INFLAMMATION; ASTROGLIA; CHEMOKINE; CYTOKINE; NEURODEGENERATIVE DISEASE;

ALPHA-SYNUCLEIN; ANIMALS; ANTIDEPRESSIVE AGENTS; ASTROCYTES; DISEASE MODELS, ANIMAL; INFLAMMATION; MICE; MICE, TRANSGENIC; MULTIPLE SYSTEM ATROPHY; NEURONS; NF-KAPPA B; OLIGODENDROGLIA;

EID: 84890140306     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.22610     Document Type: Article

References (163)

1. Aboukhatwa M, Dosanjh L, Luo Y. 2010. Antidepressants are a rational complementary therapy for the treatment of Alzheimer's disease. Mol Neurodegener 5:10.
2. Anacker C, Zunszain PA, Cattaneo A, Carvalho LA, Garabedian MJ, Thuret S, Price J, Pariante CM. 2011. Antidepressants increase human hippocampal neurogenesis by activating the glucocorticoid receptor. Mol Psychiatry 16:738-750.
3. Angot E, Steiner JA, Lema Tome CM, Ekstrom P, Mattsson B, Bjorklund A, Brundin P. 2012. Alpha-synuclein cell-to-cell transfer and seeding in grafted dopaminergic neurons in vivo. PLoS One 7:e39465.
4. Awane M, Andres PG, Li DJ, Reinecker HC. 1999. NF-kappa B-inducing kinase is a common mediator of IL-17-, TNF-alpha-, and IL-1 beta-induced chemokine promoter activation in intestinal epithelial cells. J Immunol 162:5337-5344.
5. Bachis A, Colangelo AM, Vicini S, Doe PP, De Bernardi MA, Brooker G, Mocchetti I. 2001. Interleukin-10 prevents glutamate-mediated cerebellar granule cell death by blocking caspase-3-like activity. J Neurosci 21:3104-3112.
6. Bae EJ, Lee HJ, Rockenstein E, Ho DH, Park EB, Yang NY, Desplats P, Masliah E, Lee SJ. 2012. Antibody-aided clearance of extracellular α-synuclein prevents cell-to-cell aggregate transmission. J Neurosci 32:13454-13469.
7. Balasingam V, Yong VW. 1996. Attenuation of astroglial reactivity by interleukin-10. J Neurosci 16:2945-2955.
8. Balu DT, Hoshaw BA, Malberg JE, Rosenzweig-Lipson S, Schechter LE, Lucki I. 2008. Differential regulation of central BDNF protein levels by antidepressant and non-antidepressant drug treatments. Brain Res 1211:37-43.
9. Baron R, Nemirovsky A, Harpaz I, Cohen H, Owens T, Monsonego A. 2008. IFN-gamma enhances neurogenesis in wild-type mice and in a mouse model of Alzheimer's disease. FASEB J 22:2843-2852.
10. Behr GA, Moreira JC, Frey BN. 2012. Preclinical and clinical evidence of antioxidant effects of antidepressant agents: Implications for the pathophysiology of major depressive disorder. Oxid Med Cell Longev 2012:609421.
11. Benda P, Lightbody J, Sato G, Levine L, Sweet W. 1968. Differentiated rat glial cell strain in tissue culture. Science 161:370-371.
12. Blum-Degen D, Muller T, Kuhn W, Gerlach M, Przuntek H, Riederer P. 1995. Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett 202:17-20.
13. Bodhankar S, Chen Y, Vandenbark AA, Murphy SJ, Offner H. 2013. IL-10-producing B-cells limit CNS inflammation and infarct volume in experimental stroke. Metab Brain Dis 28:375-386.
14. Braak H, Sastre M, Del Tredici K. 2007. Development of alpha-synuclein immunoreactive astrocytes in the forebrain parallels stages of intraneuronal pathology in sporadic Parkinson's disease. Acta Neuropathol 114:231-241.
15. Cao S, Standaert DG, Harms AS. 2012. The gamma chain subunit of Fc receptors is required for alpha-synuclein-induced pro-inflammatory signaling in microglia. J Neuroinflammation 9:259.
16. Cao Z, Xiong J, Takeuchi M, Kurama T, Goeddel DV. 1996. TRAF6 is a signal transducer for interleukin-1. Nature 383:443-446.
17. Chadwick W, Mitchell N, Caroll J, Zhou Y, Park SS, Wang L, Becker KG, Zhang Y, Lehrmann E, Wood WH III, Martin B, Maudsley S. 2011. Amitriptyline-mediated cognitive enhancement in aged 3xTg Alzheimer's disease mice is associated with neurogenesis and neurotrophic activity. PLoS One 6:e21660.
18. Chen L, Periquet M, Wang X, Negro A, McLean PJ, Hyman BT, Feany MB. 2009. Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation. J Clin Invest 119:3257-3265.
19. Cloonan SM, Williams DC. 2011. The antidepressants maprotiline and fluoxetine induce Type II autophagic cell death in drug-resistant Burkitt's lymphoma. Int J Cancer 128:1712-1723.
20. Cohen RM, Campbell IC, Cohen MR, Torda T, Pickar D, Siever LJ, Murphy DL. 1980. Presynaptic noradrenergic regulation during depression and antidepressant drug treatment. Psychiatry Res 3:93-105.
21. Combarros O, Infante J, Llorca J, Berciano J. 2003. Interleukin-1A (-889) genetic polymorphism increases the risk of multiple system atrophy. Mov Disord 18:1385-1386.
22. Crews L, Mizuno H, Desplats P, Rockenstein E, Adame A, Patrick C, Winner B, Winkler J, Masliah E. 2008. Alpha-synuclein alters Notch-1 expression and neurogenesis in mouse embryonic stem cells and in the hippocampus of transgenic mice. J Neurosci 28:4250-4260.
23. Darnell JE Jr, Kerr IM, Stark GR. 1994. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264:1415-1421.
24. Deleyrolle L, Marchal-Victorion S, Dromard C, Fritz V, Saunier M, Sabourin JC, Tran Van Ba C, Privat A, Hugnot JP. 2006. Exogenous and fibroblast growth factor 2/epidermal growth factor-regulated endogenous cytokines regulate neural precursor cell growth and differentiation. Stem Cells 24:748-762.
25. Desplats P, Lee HJ, Bae EJ, Patrick C, Rockenstein E, Crews L, Spencer B, Masliah E, Lee SJ. 2009. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci USA 106:13010-13015.
26. Desplats P, Spencer B, Crews L, Pathel P, Morvinski-Friedmann D, Kosberg K, Roberts S, Patrick C, Winner B, Winkler J, Masliah E. 2012. alpha-Synuclein induces alterations in adult neurogenesis in Parkinson disease models via p53-mediated repression of Notch1. J Biol Chem 287:31691-31702.
27. Di Giovanni S, Eleuteri S, Paleologou KE, Yin G, Zweckstetter M, Carrupt PA, Lashuel HA. 2010. Entacapone and tolcapone, two catechol O-methyltransferase inhibitors, block fibril formation of alpha-synuclein and beta-amyloid and protect against amyloid-induced toxicity. J Biol Chem 285:14941-14954.
28. Dickson DW, Lin W, Liu WK, Yen SH. 1999. Multiple system atrophy: A sporadic synucleinopathy. Brain Pathol 9:721-732.
29. Farrer M, Gwinn-Hardy K, Hutton M, Hardy J. 1999. The genetics of disorders with synuclein pathology and parkinsonism. Hum Mol Genet 8:1901-1905.
30. Fellner L, Irschick R, Schanda K, Reindl M, Klimaschewski L, Poewe W, Wenning GK, Stefanova N. 2013. Toll-like receptor 4 is required for alpha-synuclein dependent activation of microglia and astroglia. Glia 61:349-360.
31. Fillon G, Kahle PJ. 2005. Alpha-synuclein transgenic mice: Relevance to multiple system atrophy. Mov Disord 20 (Suppl 12):S64-S66.
32. Frank-Cannon TC, Alto LT, McAlpine FE, Tansey MG. 2009. Does neuroinflammation fan the flame in neurodegenerative diseases? Mol Neurodegener 4:47.
33. Fujisawa T, Chang MM, Velichko S, Thai P, Hung LY, Huang F, Phuong N, Chen Y, Wu R. 2011. NF-kappaB mediates IL-1beta- and IL-17A-induced MUC5B expression in airway epithelial cells. Am J Respir Cell Mol Biol 45:246-252.
34. Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, Wood NW, Colosimo C, Dürr A, Fowler CJ, Kaufmann H, Klockgether T, Lees A, Poewe W, Quinn N, Revesz T, Robertson D, Sandroni P, Seppi K, Vidailhet M. 2008. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71:670-676.
35. Griffin WS, Liu L, Li Y, Mrak RE, Barger SW. 2006. Interleukin-1 mediates Alzheimer and Lewy body pathologies. J Neuroinflamm 3:5.
36. Griffin WS, Stanley LC, Ling C, White L, MacLeod V, Perrot LJ, White CL, III, Araoz C. 1989. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci USA 86:7611-7615.
37. Hansen C, Angot E, Bergström AL, Steiner JA, Pieri L, Paul G, Outeiro TF, Melki R, Kallunki P, Fog K, Li JY, Brundin P. 2011. α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J Clin Invest 121:715-725.
38. Hashioka S. 2011. Antidepressants and neuroinflammation: Can antidepressants calm glial rage down? Mini Rev Med Chem 11:555-564.
39. Hashioka S, McGeer PL, Monji A, Kanba S. 2009. Anti-inflammatory effects of antidepressants: Possibilities for preventives against Alzheimer's disease. Cent Nerv Syst Agents Med Chem 9:12-19.
40. Haynes LE, Barber D, Mitchell IJ. 2004. Chronic antidepressant medication attenuates dexamethasone-induced neuronal death and sublethal neuronal damage in the hippocampus and striatum. Brain Res 1026:157-167.
41. Henkel AW, Welzel O, Groemer TW, Tripal P, Rotter A, Kornhuber J. 2010. Fluoxetine prevents stimulation-dependent fatigue of synaptic vesicle exocytosis in hippocampal neurons. J Neurochem 114:697-705.
42. Hisaoka K, Maeda N, Tsuchioka M, Takebayashi M. 2008. Antidepressants induce acute CREB phosphorylation and CRE-mediated gene expression in glial cells: A possible contribution to GDNF production. Brain Res 1196:53-58.
43. Hisaoka K, Nishida A, Koda T, Miyata M, Zensho H, Morinobu S, Ohta M, Yamawaki S. 2001. Antidepressant drug treatments induce glial cell line-derived neurotrophic factor (GDNF) synthesis and release in rat C6 glioblastoma cells. J Neurochem 79:25-34.
44. Infante J, Llorca J, Berciano J, Combarros O. 2005. Interleukin-8, intercellular adhesion molecule-1 and tumour necrosis factor-alpha gene polymorphisms and the risk for multiple system atrophy. J Neurol Sci 228:11-13.
45. Ishizawa K, Komori T, Sasaki S, Arai N, Mizutani T, Hirose T. 2004. Microglial activation parallels system degeneration in multiple system atrophy. J Neuropathol Exp Neurol 63:43-52.
46. Jang A, Lee HJ, Suk JE, Jung JW, Kim KP, Lee SJ. 2010. Non-classical exocytosis of alpha-synuclein is sensitive to folding states and promoted under stress conditions. J Neurochem 113:1263-1274.
47. Jellinger KA, Lantos PL. 2010. Papp-Lantos inclusions and the pathogenesis of multiple system atrophy: An update. Acta Neuropathol 119:657-667.
48. Jin Y, Lim CM, Kim SW, Park JY, Seo JS, Han PL, Yoon SH, Lee JK. 2009. Fluoxetine attenuates kainic acid-induced neuronal cell death in the mouse hippocampus. Brain Res 1281:108-116.
49. Johnstone M, Gearing AJ, Miller KM. 1999. A central role for astrocytes in the inflammatory response to beta-amyloid; chemokines, cytokines and reactive oxygen species are produced. J Neuroimmunol 93:182-193.
50. Jovanovic DV, Di Battista JA, Martel-Pelletier J, Jolicoeur FC, He Y, Zhang M, Mineau F, Pelletier JP. 1998. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. J Immunol 160:3513-3521.
51. Kamegai M, Niijima K, Kunishita T, Nishizawa M, Ogawa M, Araki M, Ueki A, Konishi Y, Tabira T. 1990. Interleukin 3 as a trophic factor for central cholinergic neurons in vitro and in vivo. Neuron 4:429-436.
52. Kayed R, Sokolov Y, Edmonds B, McIntire TM, Milton SC, Hall JE, Glabe CG. 2004. Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J Biol Chem 279:46363-46366.
53. Kim YH, Rane A, Lussier S, Andersen JK. 2011. Lithium protects against oxidative stress-mediated cell death in alpha-synuclein-overexpressing in vitro and in vivo models of Parkinson's disease. J Neurosci Res 89:1666-1675.
54. Kisos H, Pukaß K, Ben-Hur T, Richter-Landsberg C, Sharon R. 2012. Increased neuronal α-synuclein pathology associates with its accumulation in oligodendrocytes in mice modeling α-synucleinopathies. PLoS One 7:e46817.
55. Klegeris A, Pelech S, Giasson BI, Maguire J, Zhang H, McGeer EG, McGeer PL. 2008. Alpha-synuclein activates stress signaling protein kinases in THP-1 cells and microglia. Neurobiol Aging 29:739-752.
56. Knegtering H, Eijck M, Huijsman A. 1994. Effects of antidepressants on cognitive functioning of elderly patients: A review. Drugs Aging 5:192-199.
57. Kodama M, Fujioka T, Duman RS. 2004. Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat. Biol Psychiatry 56:570-580.
58. Koh SJ, Kim JM, Kim IK, Kim N, Jung HC, Song IS, Kim JS. 2011. Fluoxetine inhibits NF-kappaB signaling in intestinal epithelial cells and ameliorates experimental colitis and colitis-associated colon cancer in mice. Am J Physiol Gastrointest Liver Physiol 301:G9-G19.
59. Kohl Z, Winner B, Ubhi K, Rockenstein E, Mante M, Münch M, Barlow C, Carter T, Masliah E, Winkler J. 2012. Fluoxetine rescues impaired hippocampal neurogenesis in a transgenic A53T synuclein mouse model. Eur J Neurosci 35:10-19.
60. Kotan VO, Sarandol E, Kirhan E, Ozkaya G, Kirli S. 2011. Effects of long-term antidepressant treatment on oxidative status in major depressive disorder: A 24-week follow-up study. Prog Neuropsychopharmacol Biol Psychiatry 35:1284-1290.
61. Kubera M, Holan V, Mathison R, Maes M. 2000. The effect of repeated amitriptyline and desipramine administration on cytokine release in C57BL/6 mice. Psychoneuroendocrinology 25:785-797.
62. Laifenfeld D, Karry R, Grauer E, Klein E, Ben-Shachar D. 2005. Antidepressants and prolonged stress in rats modulate CAM-L1, laminin, and pCREB, implicated in neuronal plasticity. Neurobiol Dis 20:432-441.
63. Lalor SJ, Dungan LS, Sutton CE, Basdeo SA, Fletcher JM, Mills KH. 2011. Caspase-1-processed cytokines IL-1beta and IL-18 promote IL-17 production by gammadelta and CD4 T cells that mediate autoimmunity. J Immunol 186:5738-5748.
64. Lashuel HA, Petre BM, Wall J, Simon M, Nowak RJ, Walz T, Lansbury PT. 2002. Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J Mol Biol 322:1089-1102.
65. Lee HJ, Kim C, Lee SJ. 2010a. Alpha-synuclein stimulation of astrocytes: Potential role for neuroinflammation and neuroprotection. Oxid Med Cell Longev 3:283-287.
66. Lee HJ, Patel S, Lee SJ. 2005. Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J Neurosci 25:6016-6024.
67. Lee HJ, Suk JE, Patrick C, Bae EJ, Cho JH, Rho S, Hwang D, Masliah E, Lee SJ. 2010b. Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. J Biol Chem 285:9262-9272.
68. Lee SJ, Desplats P, Lee HJ, Spencer B, Masliah E. 2012. Cell-to-cell transmission of α-synuclein aggregates. Methods Mol Biol 849:347-359.
69. Lee SJ, Desplats P, Sigurdson C, Tsigelny I, Masliah E. 2010c. Cell-to-cell transmission of non-prion protein aggregates. Nat Rev Neurol 6:702-706.
70. Lema Tomé CM, Tyson T, Rey NL, Grathwohl S, Britschgi M, Brundin P. 2012. Inflammation and α-synuclein's prion-like behavior in Parkinson's disease-Is there a link? Mol Neurobiol 47:561-574.
71. Li GZ, Zhong D, Yang LM, Sun B, Zhong ZH, Yin YH, Cheng J, Yan BB, Li HL. 2005. Expression of interleukin-17 in ischemic brain tissue. Scand J Immunol 62:481-486.
72. Li JY, Englund E, Holton JL, Soulet D, Hagell P, Lees AJ, Lashley T, Quinn NP, Rehncrona S, Björklund A, Widner H, Revesz T, Lindvall O, Brundin P. 2008. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med 14:501-503.
73. Lieberman AP, Pitha PM, Shin HS, Shin ML. 1989. Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolysaccharide or a neurotropic virus. Proc Natl Acad Sci USA 86:6348-6352.
74. Liesz A, Zhou W, Mracsko E, Karcher S, Bauer H, Schwarting S, Sun L, Bruder D, Stegemann S, Cerwenka A, Sommer C, Dalpke AH, Veltkamp R. 2011. Inhibition of lymphocyte trafficking shields the brain against deleterious neuroinflammation after stroke. Brain 134 (Part 3):704-720.
75. Lim CM, Kim SW, Park JY, Kim C, Yoon SH, Lee JK. 2009. Fluoxetine affords robust neuroprotection in the postischemic brain via its anti-inflammatory effect. J Neurosci Res 87:1037-1045.
76. Liu BF, Gao EJ, Zeng XZ, Ji M, Cai Q, Lu Q, Yang H, Xu QY. 2006. Proliferation of neural precursors in the subventricular zone after chemical lesions of the nigrostriatal pathway in rat brain. Brain Res 1106:30-39.
77. Liu D, Wang Z, Liu S, Wang F, Zhao S, Hao A. 2011. Anti-inflammatory effects of fluoxetine in lipopolysaccharide (LPS)-stimulated microglial cells. Neuropharmacology 61:592-599.
78. Lobsiger CS, Cleveland DW. 2007. Glial cells as intrinsic components of non-cell-autonomous neurodegenerative disease. Nat Neurosci 10:1355-1360.
79. Lockhart E, Green AM, Flynn JL. 2006. IL-17 production is dominated by gammadelta T cells rather than CD4 T cells during Mycobacterium tuberculosis infection. J Immunol 177:4662-4669.
80. Louis JC, Magal E, Muir D, Manthorpe M, Varon S. 1992. CG-4, a new bipotential glial cell line from rat brain, is capable of differentiating in vitro into either mature oligodendrocytes or type-2 astrocytes. J Neurosci Res 31:193-204.
81. Malberg JE, Eisch AJ, Nestler EJ, Duman RS. 2000. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 20:9104-9110.
82. Maragakis NJ, Rothstein JD. 2006. Mechanisms of Disease: astrocytes in neurodegenerative disease. Nat Clin Pract Neurol 2:679-689.
83. McGeer PL, McGeer EG. 1995. The inflammatory response system of brain: Implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Brain Res Rev 21:195-218.
84. Menza M, Dobkin RD, Marin H, Mark MH, Gara M, Buyske S, Bienfait K, Dicke A. 2009. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 72:886-892.
85. Mogi M, Harada M, Narabayashi H, Inagaki H, Minami M, Nagatsu T. 1996. Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. Neurosci Lett 211:13-16.
86. Molina-Holgado E, Vela JM, Arévalo-Martín A, Guaza C. 2001. LPS/IFN-gamma cytotoxicity in oligodendroglial cells: Role of nitric oxide and protection by the anti-inflammatory cytokine IL-10. Eur J Neurosci 13:493-502.
87. Monje ML, Toda H, Palmer TD. 2003. Inflammatory blockade restores adult hippocampal neurogenesis. Science 302:1760-1765.
88. Mrak RE. 2009. Neuropathology and the neuroinflammation idea. J Alzheimers Dis 18:473-481.
89. Nibuya M, Morinobu S, Duman RS. 1995. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 15:7539-7547.
90. Nishimura M, Kawakami H, Komure O, Maruyama H, Morino H, Izumi Y, Nakamura S, Kaji R, Kuno S. 2002. Contribution of the interleukin-1beta gene polymorphism in multiple system atrophy. Mov Disord 17:808-811.
91. Nishimura M, Kuno S, Kaji R, Kawakami H. 2005. Influence of a tumor necrosis factor gene polymorphism in Japanese patients with multiple system atrophy. Neurosci Lett 374:218-221.
92. O'Callaghan JP, Sriram K, Miller DB. 2008. Defining "neuroinflammation." Ann N Y Acad Sci 1139:318-330.
93. Pahan K, Khan M, Singh I. 2000. Interleukin-10 and interleukin-13 inhibit proinflammatory cytokine-induced ceramide production through the activation of phosphatidylinositol 3-kinase. J Neurochem 75:576-582.
94. Papp MI, Kahn JE, Lantos PL. 1989. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J Neurol Sci 94:79-100.
95. Paumier KL, Siderowf AD, Auinger P, Oakes D, Madhavan L, Espay AJ, Revilla FJ, Collier TJ. 2012. Tricyclic antidepressants delay the need for dopaminergic therapy in early Parkinson's disease. Mov Disord 27:880-887.
96. Pechnick RN, Zonis S, Wawrowsky K, Cosgayon R, Farrokhi C, Lacayo L, Chesnokova V. 2011. Antidepressants stimulate hippocampal neurogenesis by inhibiting p21 expression in the subgranular zone of the hipppocampus. PLoS One 6:e27290.
97. Richard IH, McDermott MP, Kurlan R, Lyness JM, Como PG, Pearson N, Factor SA, Juncos J, Serrano Ramos C, Brodsky M, Manning C, Marsh L, Shulman L, Fernandez HH, Black KJ, Panisset M, Christine CW, Jiang W, Singer C, Horn S, Pfeiffer R, Rottenberg D, Slevin J, Elmer L, Press D, Hyson HC, McDonald W, SAD-PD Study Group. 2012. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology 78:1229-1236.
98. Rockenstein E, Ubhi K, Inglis C, Mante M, Patrick C, Adame A, Masliah E. 2012. Neuronal to oligodendroglial alpha-synuclein redistribution in a double transgenic model of multiple system atrophy. Neuroreport 23:259-264.
99. Rothwell NJ, Luheshi GN. 2000. Interleukin 1 in the brain: Biology, pathology and therapeutic target. Trends Neurosci 23:618-625.
100. Sadeghi H, Hajhashemi V, Minaiyan M, Movahedian A, Talebi A. 2011. A study on the mechanisms involving the anti-inflammatory effect of amitriptyline in carrageenan-induced paw edema in rats. Eur J Pharmacol 667:396-401.
101. Saijo K, Glass CK. 2011. Microglial cell origin and phenotypes in health and disease. Nat Rev Immunol 11:775-787.
102. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, Weisstaub N, Lee J, Duman R, Arancio O, Belzung C, Hen R. 2003. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301:805-809.
103. Sarkar S, Floto RA, Berger Z, Imarisio S, Cordenier A, Pasco M, Cook LJ, Rubinsztein DC. 2005. Lithium induces autophagy by inhibiting inositol monophosphatase. J Cell Biol 170:1101-1111.
104. Sawada M, Suzumura A, Hosoya H, Marunouchi T, Nagatsu T. 1999. Interleukin-10 inhibits both production of cytokines and expression of cytokine receptors in microglia. J Neurochem 72:1466-1471.
105. Schwandner R, Yamaguchi K, Cao Z. 2000. Requirement of tumor necrosis factor receptor-associated factor (TRAF)6 in interleukin 17 signal transduction. J Exp Med 191:1233-1240.
106. Schwarz SC, Seufferlein T, Liptay S, Schmid RM, Kasischke K, Foster OJ, Daniel S, Schwarz J. 1998. Microglial activation in multiple system atrophy: A potential role for NF-kappaB/rel proteins. Neuroreport 9:3029-3032.
107. Sekiyama K, Sugama S, Fujita M, Sekigawa A, Takamatsu Y, Waragai M, Takenouchi T, Hashimoto M. 2012. Neuroinflammation in Parkinson's disease and related disorders: A lesson from genetically manipulated mouse models of α-synucleinopathies. Parkinsons Dis 2012:271732.
108. Shaftel SS, Griffin WS, O'Banion MK. 2008. The role of interleukin-1 in neuroinflammation and Alzheimer disease: An evolving perspective. J Neuroinflammation 5:7.
109. Shaftel SS, Kyrkanides S, Olschowka JA, Miller JN, Johnson RE, O'Banion MK. 2007. Sustained hippocampal IL-1 beta overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology. J Clin Invest 117:1595-1604.
110. Shimizu E, Hashimoto K, Okamura N, Koike K, Komatsu N, Kumakiri C, Nakazato M, Watanabe H, Shinoda N, Okada S, Iyo M. 2003. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry 54:70-75.
111. Shults CW, Rockenstein E, Crews L, Adame A, Mante M, Larrea G, Hashimoto M, Song D, Iwatsubo T, Tsuboi K, Masliah E. 2005. Neurological and neurodegenerative alterations in a transgenic mouse model expressing human alpha-synuclein under oligodendrocyte promoter: Implications for multiple system atrophy. J Neurosci 25:10689-10699.
112. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, Gwinn-Hardy K. 2003. alpha-Synuclein locus triplication causes Parkinson's disease. Science 302:841.
113. Smith JA, Das A, Ray SK, Banik NL. 2012. Role of pro-inflammatory cytokines released from microglia in neurodegenerative diseases. Brain Res Bull 87:10-20.
114. Song C, Halbreich U, Han C, Leonard BE, Luo H. 2009. Imbalance between pro- and anti-inflammatory cytokines, and between Th1 and Th2 cytokines in depressed patients: The effect of electroacupuncture or fluoxetine treatment. Pharmacopsychiatry 42:182-188.
115. Song JH, Wang CX, Song DK, Wang P, Shuaib A, Hao C. 2005. Interferon gamma induces neurite outgrowth by up-regulation of p35 neuron-specific cyclin-dependent kinase 5 activator via activation of ERK1/2 pathway. J Biol Chem 280:12896-12901.
116. Spillantini MG. 1999. Parkinson's disease, dementia with Lewy bodies and multiple system atrophy are alpha-synucleinopathies. Parkinsonism Relat Disord 5:157-162.
117. Spillantini MG, Crowther RA, Jakes R, Cairns NJ, Lantos PL, Goedert M. 1998. Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci Lett 251:205-208.
118. Stefanova N, Tison F, Reindl M, Poewe W, Wenning GK. 2005. Animal models of multiple system atrophy. Trends Neurosci 28:501-506.
119. Streit WJ, Mrak RE, Griffin WS. 2004. Microglia and neuroinflammation: A pathological perspective. J Neuroinflammation 1:14.
120. Strle K, Zhou JH, Broussard SR, Venters HD, Johnson RW, Freund GG, Dantzer R, Kelley KW. 2002. IL-10 promotes survival of microglia without activating Akt. J Neuroimmunol 122:9-19.
121. Strle K, Zhou JH, Shen WH, Broussard SR, Johnson RW, Freund GG, Dantzer R, Kelley KW. 2001. Interleukin-10 in the brain. Crit Rev Immunol 21:427-449.
122. Sugino H, Futamura T, Mitsumoto Y, Maeda K, Marunaka Y. 2009. Atypical antipsychotics suppress production of proinflammatory cytokines and up-regulate interleukin-10 in lipopolysaccharide-treated mice. Prog Neuropsychopharmacol Biol Psychiatry 33:303-307.
123. Tai YH, Tsai RY, Lin SL, Yeh CC, Wang JJ, Tao PL, Wong CS. 2009. Amitriptyline suppresses neuroinflammation-dependent interleukin-10-p38 mitogen-activated protein kinase-heme oxygenase-1 signaling pathway in chronic morphine-infused rats. Anesthesiology 110:1379-1389.
124. Takeda A, Mallory M, Sundsmo M, Honer W, Hansen L, Masliah E. 1998. Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders. Am J Pathol 152:367-372.
125. Tang-Feldman YJ, Lochhead GR, Lochhead SR, Yu C, Pomeroy C. 2011. Interleukin-10 repletion suppresses pro-inflammatory cytokines and decreases liver pathology without altering viral replication in murine cytomegalovirus (MCMV)-infected IL-10 knockout mice. Inflamm Res 60:233-243.
126. Tatsumi M, Groshan K, Blakely RD, Richelson E. 1997. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 340:249-258.
127. Tian SS, Tapley P, Sincich C, Stein RB, Rosen J, Lamb P. 1996. Multiple signaling pathways induced by granulocyte colony-stimulating factor involving activation of JAKs, STAT5, and/or STAT3 are required for regulation of three distinct classes of immediate early genes. Blood 88:4435-4444.
128. Tokuda T, Qureshi MM, Ardah MT, Varghese S, Shehab SA, Kasai T, Ishigami N, Tamaoka A, Nakagawa M, El-Agnaf OM. 2010. Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 75:1766-1772.
129. Turbic A, Leong SY, Turnley AM. 2011. Chemokines and inflammatory mediators interact to regulate adult murine neural precursor cell proliferation, survival and differentiation. PLoS One 6:e25406.
130. Tzartos JS, Friese MA, Craner MJ, Palace J, Newcombe J, Esiri MM, Fugger L. 2008. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 172:146-155.
131. Ubhi K, Inglis C, Mante M, Patrick C, Adame A, Spencer B, Rockenstein E, May V, Winkler J, Masliah E. 2012. Fluoxetine ameliorates behavioral and neuropathological deficits in a transgenic model mouse of α-synucleinopathy. Exp Neurol 234:405-416.
132. Ubhi K, Rockenstein E, Mante M, Inglis C, Adame A, Patrick C, Whitney K, Masliah E. 2010. Neurodegeneration in a transgenic mouse model of multiple system atrophy is associated with altered expression of oligodendroglial-derived neurotrophic factors. J Neurosci 30:6236-6246.
133. Vallieres L, Campbell IL, Gage FH, Sawchenko PE. 2002. Reduced hippocampal neurogenesis in adult transgenic mice with chronic astrocytic production of interleukin-6. J Neurosci 22:486-492.
134. Valluzzi JA, Chan K. 2007. Effects of fluoxetine on hippocampal-dependent and hippocampal-independent learning tasks. Behav Pharmacol 18:507-513.
135. Vismari L, Alves GJ, Palermo-Neto J. 2010. Amitriptyline and acute inflammation: A study using intravital microscopy and the carrageenan-induced paw edema model. Pharmacology 86:231-239.
136. Volles MJ, Lee SJ, Rochet JC, Shtilerman MD, Ding TT, Kessler JC, Lansbury PT Jr. 2001. Vesicle permeabilization by protofibrillar alpha-synuclein: Implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 40:7812-7819.
137. Wakabayashi K, Hayashi S, Kakita A, Yamada M, Toyoshima Y, Yoshimoto M, Takahashi H. 1998a. Accumulation of alpha-synuclein/NACP is a cytopathological feature common to Lewy body disease and multiple system atrophy. Acta Neuropathol 96:445-452.
138. Wakabayashi K, Takahashi H. 2006. Cellular pathology in multiple system atrophy. Neuropathology 26:338-345.
139. Wakabayashi K, Yoshimoto M, Tsuji S, Takahashi H. 1998b. Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci Lett 249:180-182.
140. Wang C, McInnis J, Ross-Sanchez M, Shinnick-Gallagher P, Wiley JL, Johnson KM. 2001. Long-term behavioral and neurodegenerative effects of perinatal phencyclidine administration: Implications for schizophrenia. Neuroscience 107:535-550.
141. Wang JW, David DJ, Monckton JE, Battaglia F, Hen R. 2008. Chronic fluoxetine stimulates maturation and synaptic plasticity of adult-born hippocampal granule cells. J Neurosci 28:1374-1384.
142. Wang X, Fu S, Wang Y, Yu P, Hu J, Gu W, Xu XM, Lu P. 2007. Interleukin-1beta mediates proliferation and differentiation of multipotent neural precursor cells through the activation of SAPK/JNK pathway. Mol Cell Neurosci 36:343-354.
143. Watanabe H, Saito Y, Terao S, Ando T, Kachi T, Mukai E, Aiba I, Abe Y, Tamakoshi A, Doyu M, Hirayama M, Sobue G. 2002. Progression and prognosis in multiple system atrophy: An analysis of 230 Japanese patients. Brain 125 (Part 5):1070-1083.
144. Watson MB, Richter F, Lee SK, Gabby L, Wu J, Masliah E, Effros RB, Chesselet MF. 2012. Regionally-specific microglial activation in young mice over-expressing human wildtype alpha-synuclein. Exp Neurol 237:318-334.
145. Welham MJ, Learmonth L, Bone H, Schrader JW. 1995. Interleukin-13 signal transduction in lymphohemopoietic cells. Similarities and differences in signal transduction with interleukin-4 and insulin. J Biol Chem 270:12286-12296.
146. Wenning GK, Jellinger KA. 2005. The role of alpha-synuclein in the pathogenesis of multiple system atrophy. Acta Neuropathol 109:129-140.
147. Winner B, Jappelli R, Maji SK, Desplats PA, Boyer L, Aigner S, Hetzer C, Loher T, Vilar M, Campioni S, Tzitzilonis C, Soragni A, Jessberger S, Mira H, Consiglio A, Pham E, Masliah E, Gage FH, Riek R. 2011. In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci USA 108:4194-4199.
148. Winner B, Lie DC, Rockenstein E, Aigner R, Aigner L, Masliah E, Kuhn HG, Winkler J. 2004. Human wild-type alpha-synuclein impairs neurogenesis. J Neuropathol Exp Neurol 63:1155-1166.
149. Winner B, Regensburger M, Schreglmann S, Boyer L, Prots I, Rockenstein E, Mante M, Zhao C, Winkler J, Masliah E, Gage FH. 2012. Role of α-synuclein in adult neurogenesis and neuronal maturation in the dentate gyrus. J Neurosci 32:16906-16916.
150. Winner B, Rockenstein E, Lie DC, Aigner R, Mante M, Bogdahn U, Couillard-Despres S, Masliah E, Winkler J. 2008. Mutant alpha-synuclein exacerbates age-related decrease of neurogenesis. Neurobiol Aging 29:913-925.
151. Wong G, Goldshmit Y, Turnley AM. 2004. Interferon-gamma but not TNF alpha promotes neuronal differentiation and neurite outgrowth of murine adult neural stem cells. Exp Neurol 187:171-177.
152. Wyss-Coray T, Mucke L. 2002. Inflammation in neurodegenerative disease-A double-edged sword. Neuron 35:419-432.
153. Yau JL, Noble J, Hibberd C, Rowe WB, Meaney MJ, Morris RG, Seckl JR. 2002. Chronic treatment with the antidepressant amitriptyline prevents impairments in water maze learning in aging rats. J Neurosci 22:1436-1442.
154. Yazawa I, Giasson BI, Sasaki R, Zhang B, Joyce S, Uryu K, Trojanowski JQ, Lee VM. 2005. Mouse model of multiple system atrophy alpha-synuclein expression in oligodendrocytes causes glial and neuronal degeneration. Neuron 45:847-859.
155. Yoshida M. 2007. Multiple system atrophy: Alpha-synuclein and neuronal degeneration. Neuropathology 27:484-493.
156. Yuan XQ, Qiu G, Liu XJ, Liu S, Wu Y, Wang X, Lu T. 2012. Fluoxetine promotes remission in acute experimental autoimmune encephalomyelitis in rats. Neuroimmunomodulation 19:201-208.
157. Zambrano A, Otth C, Mujica L, Concha II, Maccioni RB. 2007. Interleukin-3 prevents neuronal death induced by amyloid peptide. BMC Neurosci 8:82.
158. Zhang D, Hu X, Qian L, O'Callaghan JP, Hong JS. 2010. Astrogliosis in CNS pathologies: Is there a role for microglia? Mol Neurobiol 41:232-241.
159. Zhang F, Zhou H, Wilson BC, Shi JS, Hong JS, Gao HM. 2012. Fluoxetine protects neurons against microglial activation-mediated neurotoxicity. Parkinsonism Relat Disord 18 (Suppl 1):S213-S217.
160. Zhang W, Wang T, Pei Z, Miller DS, Wu X, Block ML, Wilson B, Zhang W, Zhou Y, Hong JS, Zhang J. 2005. Aggregated alpha-synuclein activates microglia: A process leading to disease progression in Parkinson's disease. FASEB J 19:533-542.
161. Zhou Z, Peng X, Insolera R, Fink DJ, Mata M. 2009. Interleukin-10 provides direct trophic support to neurons. J Neurochem 110:1617-1627.
162. Zimmermann J, Krauthausen M, Hofer MJ, Heneka MT, Campbell IL, Muller M. 2013. CNS-targeted production of IL-17A induces glial activation, microvascular pathology and enhances the neuroinflammatory response to systemic endotoxemia. PLoS One 8:e57307.
163. Zschocke J, Rein T. 2011. Antidepressants encounter autophagy in neural cells. Autophagy 7:1247-1248.